Women who develop preeclampsia during pregnancy face a significantly elevated risk of cardiovascular disease later in life, yet most receive no systematic cardiac monitoring after delivery. This gap leaves millions of women vulnerable to undetected heart problems that could be prevented or managed with early intervention.
Researchers have identified several promising biomarkers that persist after preeclampsia pregnancies and signal ongoing cardiovascular risk. Elevated levels of antiangiogenic factors like sFlt1 and soluble endoglin during pregnancy correlate with subtle heart dysfunction and postpartum hypertension. Years later, persistently high interleukin-6 levels indicate chronic systemic inflammation, while elevated activin A suggests continued cardiac stress. The sFlt1/PlGF ratio emerges as particularly useful for risk stratification.
Advanced cardiac imaging techniques complement these biomarker approaches. Global longitudinal strain measurement via echocardiography can detect early heart muscle impairment before traditional measures show abnormalities, offering a window for preventive intervention. Non-invasive hemodynamic monitoring tools like USCOM may help optimize blood pressure management in this high-risk population.
This represents a significant advancement in personalized cardiovascular medicine. Preeclampsia affects roughly 5-8% of pregnancies globally, creating a substantial population of women who could benefit from targeted screening protocols. However, most findings come from relatively small studies with limited long-term follow-up. The field needs larger prospective trials to validate these biomarkers and establish evidence-based guidelines for post-preeclampsia cardiovascular surveillance. Until then, the promise of precision prevention remains largely unrealized for this vulnerable population.